<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03867071</url>
  </required_header>
  <id_info>
    <org_study_id>PHRCI/2004/AC-01</org_study_id>
    <nct_id>NCT03867071</nct_id>
  </id_info>
  <brief_title>Early Administration of Recombinant Erythropoietin (RHEPO) in Transfusion Savings in Trauma Patients</brief_title>
  <acronym>EPREX</acronym>
  <official_title>Early Administration of Recombinant Erythropoietin (RHEPO) in Transfusion Savings in Trauma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of our study is to demonstrate the interest of early administration of
      recombinant erythropoietin in trauma patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Could an early use of rHuEPO (recombinant Human ErythroPOietin ) be lead to an individual
      benefice on transfusion savings after traumatic surgery?
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2005</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of administered red blood cells</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Trauma</condition>
  <arm_group>
    <arm_group_label>erythropoietin (EPO) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (PLA) group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>recombinant erythropoietin injection</intervention_name>
    <description>Intravenous injection of 300 international units (IU) per kg (kg) of recombinant erythropoietin with a maximum of 20.000 IU, daily for a maximum of 10 days (D0 to D9).</description>
    <arm_group_label>erythropoietin (EPO) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo injection</intervention_name>
    <description>Intravenous injection 0,9% saline solution.</description>
    <arm_group_label>Placebo (PLA) group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 18 to 65 years old

          -  Patient with an ASA 1 or 2 (ASA 1 corresponding to a patient in perfect health and ASA
             2 to a patient with moderate involvement and well controlled organ function)

          -  patient presenting at least one of the following fractures: Basin and / or femur with
             surgical indication, associated or not with other fractures.

          -  patient with hemoglobin between 9 and 13 g / dl at the time of admission on trauma
             department

        Exclusion Criteria:

          -  patient with contraindication to synthetic erythropoietin

          -  Patient with intravenous iron contraindication

          -  pregnant patient or with a risk of pregnancy

          -  patient who has not given his consent or does not understand the protocol

          -  Patient with hemodynamic instability

          -  patient participating in another research protocol for less than 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nimes university hospital</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>March 6, 2019</last_update_submitted>
  <last_update_submitted_qc>March 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

